Telix Pharmaceuticals sued for false and misleading statements about prostate cancer treatments.

Telix Pharmaceuticals is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934. The lawsuit claims that the company made false and misleading statements about its progress in developing and commercializing prostate cancer treatments and overstated the strength of its supply chain. The class period is from February 21, 2025 to August 28, 2025, and the deadline to file a complaint is January 9, 2026.